Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

Vertebral fractures: a hidden problem of osteoporosis

Józef Haczyński, Artur J. Jakimiuk

Med Sci Monit 2001; 7(5): RA1108-1117 :: ID: 509387


Osteoporosis is a progressive skeletal disease, which in many cases remains silent and asymptomatic until a fracture occurs. Vertebral fractures are the earliest and most common osteoporotic fractures. The prevalence of vertebral fractures increases steadily with age, ranging between 20% for 50-year-old postmenopausal women to 64.5% for older women. The majority of vertebral fractures are not connected with severe trauma, and only one in three is diagnosed clinically. Usually vertebral fractures are associated with such clinical symptoms as back pain, posture change, loss of height, functional impairment, disability, and diminished quality of live. Women with the most severe vertebral fractures are the most likely to incur further fractures, with as much as 3.4 times the risk of hip fracture, and 12.6 times the risk of new vertebral fractures. Almost 20% of women will experience another fracture within 1 year after a vertebral fracture. Vertebral fractures are accompanied by increased mortality. The relative risk of death following vertebral fracture is almost 9 times higher. The most important purpose of osteoporosis management in postmenopausal women is prevention of the first vertebral fracture. Raloxifene (Evista) is the only SERM approved by the American FDA for the treatment and prevention of osteoporosis. It is the first compound with selective estrogen agonist activity in bone and in the cardiovascular system, but with estrogen antagonist activity or no activity in reproductive tissues and breast. Raloxifene reduces the risk of positive estrogen receptor breast cancer, decreases total cholesterol and LDL cholesterol, increases HDL cholesterol, does not increase the risk of endometrial cancer or cause bleeding and spotting. After 3 years of treatment Raloxifene reduces the risk of first vertebral fracture by 55%. The fracture risk within one year is reduced by as much as 68%. Continued observation has proved its sustained efficacy in the further reduction of fracture risk by 49% in the fourth year. Raloxifene treatment does not change the physiological structure of bone quality and does not cause fibrosis, osteomalacia or other toxic effects.

Keywords: Osteoporosis, vertebral fracture, Raloxifene



01 March 2023 : Editorial  

Editorial: Global Surveillance of Highly Pathogenic Avian Influenza Viruses in Poultry, Wild Birds, and Mammals to Prevent a Human Influenza Pandemic

Dinah V. Parums

DOI: 10.12659/MSM.939968

Med Sci Monit 2023; 29:e939968


03 March 2023 : Database Analysis  

Reinfections from SARS-CoV-2: A Retrospective Study from the Gyncentrum Genetic Laboratory in Sosnowiec, Po...

Med Sci Monit In Press; DOI: 10.12659/MSM.939452  

09 February 2023 : Clinical Research  

Evaluation of Health-Related Quality of Life and Mental Health in 729 Medical Students in Indonesia During ...

Med Sci Monit 2023; 29:e938892

27 December 2022 : Clinical Research  

Effect of Physiotherapy to Correct Rounded Shoulder Posture in 30 Patients During the COVID-19 Pandemic in ...

Med Sci Monit 2022; 28:e938926

In Press

20 Mar 2023 : Clinical Research  

Management of Unstable C1 Fractures Involving the Lateral Mass: Posterior C1-C2 Screw-Rod Fixation and Fusion

Med Sci Monit In Press; DOI: 10.12659/MSM.938600  

17 Mar 2023 : Clinical Research  

Relationship Between Autonomic Nervous System Activity and Axial Length in Children

Med Sci Monit In Press; DOI: 10.12659/MSM.939451  

15 Mar 2023 : Clinical Research  

Relationship Between Psychological Symptoms and Self-Esteem Levels Before and After Stomach Botox Treatment

Med Sci Monit In Press; DOI: 10.12659/MSM.939618  

15 Mar 2023 : Clinical Research  

Short-Term Patient Outcomes Using the Interlaminar Endoscopic Surgical System Ilessys® Delta System versus ...

Med Sci Monit In Press; DOI: 10.12659/MSM.938477  

Most Viewed Current Articles

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750